Stress reduction and emotional regulation (psychobiotic effects)
B. longum 1714 is one of the few probiotics with direct clinical evidence for stress and mood effects in healthy adults. Multiple RCTs (4-week supplementation, 1 billion CFU/day) show reduced cumulative stress responses on the Cold Pressor Test, improved sleep quality, reduced cortisol response to acute stressors, and altered EEG patterns suggesting enhanced emotional processing. Considered the most-studied 'psychobiotic' globally.
IBS symptom improvement (35624 strain)
B. longum 35624 (subspecies infantis, marketed as Align®) demonstrated significant IBS symptom reduction in multiple multicenter RCTs. A landmark trial in 362 women with IBS showed 35624 (10^8 CFU/day) significantly improved abdominal pain/discomfort, bloating, bowel dysfunction, and global IBS symptoms over 4 weeks. Higher and lower doses (10^6, 10^10) were ineffective — strict dose-dependence.
Allergy symptom reduction (BB536 strain)
B. longum BB536 has multiple RCTs showing reductions in seasonal allergic rhinitis (Japanese cedar pollen) symptoms, atopic dermatitis severity in infants, and milk/egg allergic reactions in challenge tests. Mechanism involves Th1/Th2 balance restoration via dendritic cell modulation.
Constipation relief in elderly
B. longum (especially BB536) significantly improves bowel regularity in elderly populations and patients with chronic functional constipation. Effects are most pronounced after 4+ weeks of supplementation. Stool frequency increases and stool consistency normalizes via SCFA production stimulating colonic motility.
Vagal nerve signaling for gut-brain axis
B. longum 1714 modulates vagal nerve afferent signaling from the gut to the brainstem, influencing emotional processing centers. Animal studies show vagotomy abolishes psychobiotic effects, confirming vagus nerve as the primary signaling pathway. EEG changes in 1714-supplemented subjects support central nervous system effects.
GABA and tryptophan metabolite production
B. longum produces GABA (the primary inhibitory neurotransmitter in the brain) via glutamate decarboxylase and modulates tryptophan/serotonin metabolism in the gut. While GABA itself doesn't cross the blood-brain barrier well, gut-derived GABA influences enteric nervous system signaling and indirect CNS effects.
HMO (human milk oligosaccharide) utilization
B. longum subspecies infantis is uniquely adapted to metabolize human milk oligosaccharides — a feature shared with very few other gut bacteria. This explains its dominance in breastfed infant guts and its specific value in infant formula/probiotic supplementation. The HMO-utilization gene cluster encodes specialized transporters and glycosidases.
SCFA production and HPA axis modulation
Through fermentation of dietary fibers and HMOs, B. longum produces acetate and lactate, which feed butyrate-producing bacteria. Resulting butyrate crosses gut-blood barrier and modulates HPA axis sensitivity, reducing cortisol reactivity to stressors. This is a likely mechanism for the psychobiotic effects observed clinically.
Randomized, double-blind, placebo-controlled crossover trial. Healthy male adults received B. longum 1714 (10^9 CFU/day) or placebo for 4 weeks each, with washout between phases. Multiple stress, mood, and cognitive assessments performed.
22 healthy male adults.
B. longum 1714 reduced cumulative cortisol response to social stressor (Trier Social Stress Test variant), improved subjective stress ratings, enhanced visual memory performance under stress, and produced EEG changes (increased frontal theta) suggesting enhanced emotional regulation. First clinical evidence of probiotic-induced behavioral and brain changes in healthy humans.
Randomized, double-blind, placebo-controlled trial with three probiotic doses (10^6, 10^8, 10^10 CFU/day) and placebo over 4 weeks.
362 women with IBS per Rome II criteria.
10^8 CFU/day dose significantly improved IBS composite symptom score and individual symptoms (pain, bloating, bowel dysfunction). Higher and lower doses were ineffective — demonstrating strict dose-dependence (related to encapsulation/viability). Established 35624 as IBS-specific probiotic.
13-week, randomized, double-blind, placebo-controlled trial during cedar pollen season. Subjects received yogurt with B. longum BB536 (10^11 CFU/day) or plain yogurt.
44 adults with documented Japanese cedar pollinosis.
Significant reductions in eye symptoms, eye drop usage, throat symptoms, and serum IgE (cedar-specific). Effects most pronounced during peak pollen weeks. Follow-up trials have replicated these findings with various dose protocols.